Last updated: August 2, 2026
Dalbavancin hydrochloride is a long-acting lipoglycopeptide antibiotic marketed in the United States as Dalvance and in Europe as Xydalba. Its commercial value comes from single-dose or two-dose treatment for acute bacterial skin and skin-structure infections, particularly when outpatient administration can replace multi-day intravenous vancomycin. The product has durable clinical differentiation but a limited addressable market, weak public financial transparency, and continuing pressure from lower-cost antibiotics and hospital stewardship programs.
Publicly available sources do not provide a current, standalone global revenue series for dalbavancin. The product is marketed by private or diversified companies that generally report portfolio-level results rather than drug-specific sales.
What is dalbavancin hydrochloride used for?
Dalbavancin hydrochloride is an intravenous lipoglycopeptide antibiotic that inhibits bacterial cell-wall synthesis. The U.S. Food and Drug Administration approved Dalvance in May 2014 for acute bacterial skin and skin-structure infections caused by susceptible Gram-positive organisms, including methicillin-resistant Staphylococcus aureus in labeled circumstances (FDA, 2014).
The main clinical advantages are:
- A long terminal half-life of approximately 8.5 days.
- A two-dose regimen administered one week apart.
- A single 1,500 mg infusion option for adults.
- Reduced need for peripherally inserted central catheters and daily outpatient infusion.
- Activity against many Gram-positive pathogens, including MRSA.
The principal commercial limitation is that dalbavancin is an intravenous hospital product. It does not address Gram-negative infections, has no oral formulation, and is not a general replacement for broad-spectrum empiric therapy.
What formulations are protected by dalbavancin patents?
The commercial product is an intravenous formulation supplied as a sterile lyophilized powder for reconstitution. Its value is concentrated in the active pharmaceutical ingredient, injectable formulation, dosing regimen, manufacturing process, and methods of treating bacterial infections.
No commercially established oral, subcutaneous, inhaled, or depot formulation has replaced the intravenous product. A successful alternative delivery system could expand use in outpatient and community settings, but it could also create additional regulatory and manufacturing requirements.
When did the FDA approve Dalvance and how has the label evolved?
The FDA approved Dalvance in 2014 under the 505(b)(1) new drug application pathway. The original label supported treatment of acute bacterial skin and skin-structure infections in adults. Subsequent labeling expanded the treated population and clarified dosing options.
| Milestone |
Date |
Commercial significance |
| FDA approval of Dalvance |
May 2014 |
Established U.S. regulatory exclusivity and commercial launch |
| Single-dose adult regimen added |
2016 |
Improved outpatient convenience and reduced administration burden |
| Pediatric indication added |
2021 |
Expanded labeled population to patients aged 3 months and older |
| Current core indication |
Through 2024 |
Acute bacterial skin and skin-structure infections caused by susceptible Gram-positive bacteria |
The product’s most important regulatory asset is the dosing profile rather than a broad indication. Off-label use in bacteremia, endocarditis, osteomyelitis, and other deep-seated infections has supported clinical interest, but those uses do not automatically receive the same regulatory or reimbursement treatment as the approved indication.
How large is the dalbavancin market?
Dalbavancin operates in a focused segment of the hospital and outpatient parenteral antibiotic therapy market. The commercial opportunity is driven by treatment setting rather than by disease prevalence alone.
Key demand drivers
Hospitals and clinicians may use dalbavancin when:
- A patient is clinically stable but requires continued Gram-positive coverage.
- Daily vancomycin monitoring is impractical.
- A patient is at high risk of line-related complications.
- The patient is unlikely to complete a conventional outpatient regimen.
- Hospital discharge creates a meaningful cost or capacity benefit.
- A long-acting antibiotic can avoid placement or maintenance of an intravenous catheter.
Emergency departments, observation units, outpatient infusion centers, skilled nursing facilities, and hospital-at-home programs are the principal expansion channels.
Main market constraints
Dalbavancin remains exposed to:
- High acquisition cost compared with generic vancomycin.
- Reimbursement differences between inpatient and outpatient settings.
- Hospital antimicrobial stewardship restrictions.
- Lack of Gram-negative coverage.
- Limited randomized evidence for many off-label uses.
- Budget pressure on hospitals and managed-care organizations.
- Competitive long-acting therapy from oritavancin.
The economic case is strongest when the product prevents a hospital admission, shortens inpatient stay, avoids a central line, or replaces multiple visits. The case is weaker when a patient can safely receive inexpensive oral therapy or generic vancomycin.
How does dalbavancin compare with competing antibiotics?
| Product |
Administration |
Main commercial strength |
Main weakness |
| Dalbavancin |
One dose or two weekly doses |
Long duration and outpatient convenience |
High acquisition cost and narrow Gram-positive spectrum |
| Oritavancin |
Generally single intravenous dose |
One-time administration |
Similar cost and stewardship limitations |
| Vancomycin |
Daily intravenous dosing, often with monitoring |
Low generic cost and extensive clinical experience |
Monitoring, line complications, and operational burden |
| Linezolid |
Oral or intravenous |
Oral step-down and broad outpatient utility |
Hematologic, neurologic, and drug-interaction concerns |
| Ceftaroline |
Repeated intravenous dosing |
Broad MRSA-active cephalosporin profile |
Frequent administration and higher treatment burden |
| Tedizolid |
Oral or intravenous |
Short-course treatment option |
Lower role in severe or complex infections |
Dalbavancin’s strongest competitive position is against prolonged intravenous vancomycin, not against oral antibiotics. Oritavancin is the closest direct comparator because both products offer long-acting treatment. Vancomycin remains the price benchmark.
What is the financial trajectory for dalbavancin?
The financial trajectory has passed through three ownership phases:
- Durata Therapeutics developed and launched Dalvance.
- Actavis acquired Durata in 2014, shortly after approval.
- Allergan inherited the product through the Actavis-Allergan combination, while Melinta later acquired a portfolio of anti-infective products and associated commercial rights.
The product has generated commercial value through licensing, acquisition, and portfolio transactions. Public filings have not consistently disclosed annual Dalvance revenue as a separate line item.
Financial assessment
| Financial factor |
Assessment |
| Revenue visibility |
Low; drug-specific sales are generally not separately reported |
| Pricing power |
Moderate to high on a per-course basis |
| Volume growth |
Constrained by narrow indication and stewardship controls |
| Margin potential |
Potentially attractive because dosing is infrequent, but manufacturing is complex |
| Reimbursement risk |
Material, especially where hospital payment does not capture avoided outpatient costs |
| Growth catalyst |
Hospital-at-home, emergency-department discharge, and outpatient infusion |
| Downside risk |
Generic competition, price concessions, and reduced use in uncomplicated infections |
Dalbavancin is better characterized as a specialized revenue and margin product than as a high-volume anti-infective franchise. Its economic performance depends on site-of-care conversion. A shift from inpatient treatment to outpatient administration can increase product use, but hospitals may resist adoption if the drug cost is booked immediately while avoided costs accrue elsewhere.
Which companies market or control dalbavancin?
The principal commercial entities associated with dalbavancin include:
- Durata Therapeutics, the original developer and U.S. launch company.
- Actavis, which acquired Durata in 2014.
- Allergan, which later owned the product through corporate consolidation.
- Melinta Therapeutics, which acquired commercial rights to a portfolio of hospital anti-infective products.
- Advanz Pharma and other regional partners associated with European commercialization of Xydalba.
Commercial rights vary by geography and transaction. U.S. rights, European rights, and manufacturing rights should not be assumed to reside with the same entity.
The competitive landscape is fragmented. No company has established dalbavancin as a broad, first-line replacement for conventional antibiotics. Commercial success depends on hospital contracting, infectious-disease physician adoption, payer coverage, and reliable supply of the active ingredient and sterile injectable product.
What is the Orange Book and generic-entry status of Dalvance?
Dalvance is an FDA-approved small-molecule injectable product and is therefore potentially subject to an Abbreviated New Drug Application pathway. Generic competition would require an applicant to address the active ingredient, dosage form, strength, route of administration, pharmaceutical equivalence, and applicable listed patents or exclusivity.
The main regulatory barriers are:
- Complex sterile injectable manufacturing.
- Control of impurities and degradation products.
- Demonstration of pharmaceutical equivalence.
- Reliable supply of a complex glycopeptide active ingredient.
- Potential patent certifications under Paragraph IV.
- Commercial difficulty in entering a relatively small market.
A complete current Orange Book patent and exclusivity determination requires the FDA’s live product and patent listings. Publicly available commercial materials do not establish a reliable, current expiration date for every listed Dalvance patent. Patent expiry should therefore be assessed by reviewing the latest FDA Orange Book entry and the underlying U.S. Patent and Trademark Office records, rather than relying on secondary databases.
What generic entry risks exist for dalbavancin?
The near-term generic risk is likely to be driven more by economics and manufacturing than by rapid clinical substitution.
Paragraph IV challenges
A generic applicant could file an ANDA with a Paragraph IV certification against listed patents. The sponsor would then face potential patent litigation and a statutory 30-month stay of approval under the Hatch-Waxman framework if the innovator filed suit within the applicable period.
The commercial impact of a Paragraph IV filing would depend on:
- The number and scope of Orange Book-listed patents.
- Whether listed claims cover the active ingredient, formulation, dosing regimen, or manufacturing method.
- The strength of infringement and validity positions.
- The size of the addressable market.
- The ability of the generic company to manufacture the injectable product at scale.
A Paragraph IV filing would not guarantee an early launch. It could, however, reduce contracting leverage and accelerate payer pressure before final generic approval.
Generic launch scenarios
| Scenario |
Market effect |
| No approved generic |
Branded pricing remains relatively durable, with selective hospital discounts |
| First generic approval |
Large price reduction in tender-driven accounts; slower conversion where clinical protocols favor branded supply |
| Multiple injectable generics |
Accelerated price erosion and reduced differentiation |
| Authorized generic or licensed entrant |
Controlled price competition with possible supply stability |
| Patent settlement |
Entry date depends on the agreement and any Federal Trade Commission or court scrutiny |
How strong is the dalbavancin patent estate?
The patent estate has potential protection across several layers:
- Composition of matter.
- Glycopeptide derivatives and antibacterial compounds.
- Pharmaceutical compositions.
- Dosing regimens.
- Treatment methods.
- Manufacturing and purification processes.
Composition patents generally provide the strongest exclusionary position. Formulation, dosing, and method-of-use patents can extend commercial protection but may be more vulnerable to validity, claim-construction, or non-infringement challenges.
The practical strength of the estate is affected by the product’s narrow market. A generic challenger may tolerate litigation costs if it expects rapid hospital adoption, but a small market can also deter a Paragraph IV filing. Manufacturing patents may delay supply entry even after core composition protection expires, particularly if the active ingredient requires specialized fermentation, purification, or sterile fill-finish capabilities.
What patent litigation affects dalbavancin?
No major, widely reported U.S. Paragraph IV litigation campaign against Dalvance is established in the principal public sources reviewed through 2024. The absence of prominent litigation does not establish that no patent disputes, licensing negotiations, or abbreviated applications exist.
The most relevant legal risks are likely to involve:
- Orange Book-listed patents.
- Patent-term adjustment and pediatric extension calculations.
- Method-of-use claims covering long-acting dosing.
- Manufacturing process claims.
- Settlement agreements with potential early-entry dates.
- Trade-secret protection for fermentation and purification processes.
A litigation event would materially change the product’s valuation because the standalone commercial market is concentrated and sensitive to the first generic entrant.
What licensing deals and acquisitions shaped dalbavancin?
Dalbavancin’s commercial history is closely linked to corporate transactions rather than a standalone licensing platform.
| Transaction or event |
Strategic effect |
| Durata development and FDA approval |
Created the original commercial asset |
| Actavis acquisition of Durata |
Moved Dalvance into a larger specialty-pharma portfolio |
| Actavis-Allergan combination |
Added the product to Allergan’s anti-infective holdings |
| Transfer of anti-infective assets to Melinta |
Repositioned commercialization under a hospital-focused anti-infective company |
| Regional European commercialization arrangements |
Expanded Xydalba access outside the United States |
Deal terms have generally not provided a clean, continuing public revenue bridge for dalbavancin. Valuation should focus on rights territory, remaining patent life, manufacturing obligations, minimum purchase commitments, and hospital-account concentration.
What is the geographic coverage of dalbavancin?
Dalbavancin has U.S. FDA approval as Dalvance and European authorization as Xydalba. European commercialization is subject to country-level pricing, reimbursement, procurement, and hospital formulary decisions.
Geographic performance is likely to vary because:
- The United States has greater use of outpatient infusion and hospital-at-home models.
- European markets apply stronger national or regional price controls.
- Hospital procurement can favor lower-cost alternatives.
- Antibiotic stewardship policies differ by country.
- The long-acting regimen has greater value where outpatient infrastructure is limited.
The principal geographic growth opportunity is not simply expansion into more countries. It is deeper penetration into outpatient pathways in markets where reimbursement recognizes avoided hospital and infusion costs.
What generic and biosimilar competition should investors monitor?
Dalbavancin is a small-molecule antibiotic, so biosimilar competition does not apply. The relevant threat is generic competition through the ANDA pathway.
Investors should monitor:
- FDA Orange Book changes.
- ANDA approvals for dalbavancin hydrochloride.
- Paragraph IV litigation notices.
- Hospital formulary removals or restrictions.
- Net price changes and tender losses.
- Manufacturing-site changes.
- New long-acting antibiotic entrants.
- Clinical-trial evidence supporting off-label use.
- Payer policies covering outpatient infusion.
A new long-acting Gram-positive antibiotic could pressure dalbavancin even without generic entry if it offers lower cost, broader labeling, easier administration, or superior reimbursement.
Key Takeaways
- Dalbavancin hydrochloride is a differentiated, long-acting intravenous antibiotic rather than a high-volume broad-spectrum product.
- Its commercial value is concentrated in outpatient treatment, hospital discharge, and avoidance of daily vancomycin administration.
- The principal branded products are Dalvance in the United States and Xydalba in Europe.
- Public companies have not consistently disclosed standalone dalbavancin revenue, limiting precision in financial forecasting.
- Growth depends on site-of-care conversion, hospital-at-home adoption, and reimbursement alignment.
- Vancomycin remains the main economic benchmark, while oritavancin is the closest direct therapeutic competitor.
- Generic risk is primarily an ANDA and sterile-manufacturing issue. Biosimilar risk does not apply.
- The current Orange Book patent position and exact generic-entry date require live FDA and USPTO verification.
- Manufacturing complexity may remain a meaningful barrier after core patent protection expires.
- The product has a defensible niche, but its valuation is sensitive to first-generic timing, hospital contracting, and net pricing.
FAQs About Dalbavancin Hydrochloride
Is dalbavancin hydrochloride a generic drug?
No. Dalbavancin hydrochloride is the active ingredient in branded Dalvance and Xydalba. Generic versions could be approved through the ANDA pathway if they meet FDA requirements and overcome applicable patent barriers.
How long does one dose of dalbavancin last?
Dalbavancin has a terminal half-life of approximately 8.5 days. The FDA-approved adult regimens include a single 1,500 mg infusion or two doses administered one week apart, depending on the labeled regimen and clinical circumstances.
Is dalbavancin more expensive than vancomycin?
The acquisition cost of a dalbavancin course is generally much higher than the drug cost of generic vancomycin. Its economic justification depends on avoided hospitalization, infusion visits, therapeutic monitoring, catheter placement, and treatment nonadherence.
Can dalbavancin treat endocarditis or osteomyelitis?
Dalbavancin is used off label for some deep-seated infections, including osteomyelitis and endocarditis. Those uses are distinct from the FDA-approved acute bacterial skin and skin-structure infection indication and may have different reimbursement and evidence profiles.
Does dalbavancin have biosimilar competition?
No. Dalbavancin is a small-molecule antibiotic, not a biologic. Competition would come from generic versions, alternative antibiotics, or new long-acting anti-infective products.
References
- U.S. Food and Drug Administration. (2014). FDA approves Dalvance to treat skin infections. https://www.fda.gov
- U.S. Food and Drug Administration. (2021). Dalvance prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- Actavis plc. (2014). Annual report 2014.
- Allergan plc. (2019). Annual report 2019.
- Melinta Therapeutics. (n.d.). Dalvance product information. https://www.melinta.com
- European Medicines Agency. (n.d.). Xydalba: EPAR product information. https://www.ema.europa.eu
- Dunbar, L. M., Milata, J., McClure, T., & Wasilewski, M. M. (2014). Comparison of the efficacy and safety of once-weekly dalbavancin versus conventional therapy for acute bacterial skin and skin-structure infections. Clinical Infectious Diseases, 59(7), 935-943.
